Recent Comments

Comment RSS

Arthritis News and Research RSS Feed - Arthritis News and Research Twitter

Many people start to feel pain and stiffness in their bodies over time. Sometimes their hands or knees or shoulders get sore and are hard to move and may become swollen. These people may have arthritis. Arthritis may be caused by inflammation of the tissue lining the joints. Some signs of inflammation include redness, heat, pain, and swelling. These problems are telling you that something is wrong. Joints are places where two bones meet, such as your elbow or knee. Over time, in some types of arthritis but not in all, the joints involved can become severely damaged. There are different types of arthritis. In some diseases in which arthritis occurs, other organs, such as your eyes, your chest, or your skin, can also be affected. Some people may worry that arthritis means they won’t be able to work or take care of their children and their family. Others think that you just have to accept things like arthritis.

Ligand Pharmaceuticals' SARM LGD-4033 study data presented at the Gerontology Society of America meeting

20. November 2009 08:37
Ligand Pharmaceuticals Incorporated today announced that data from a preclinical study on its selective androgen receptor modulator (SARM) LGD-4033 was featured in a poster presentation at the 62nd Annual Meeting of the Gerontology Society of America in Atlanta. LGD-4033 exhibited desirable in vivo efficacy on skeletal muscle and bone measurements in animal models of male hypogonadism and postmenopausal osteoporosis. [More]

Report on orthopedic prosthetic devices market

20. November 2009 04:18
Research and Markets (http://www.researchandmarkets.com/research/7b62a4/orthopedic_prosthe) has announced the addition of the "Orthopedic Prosthetics - A World Market Review" report to their offering. [More]

Posted in: Device / Technology News

Tags: , , , ,

Ligand Pharmaceuticals receives $2 million in milestone payments from N. V. Organon

19. November 2009 22:41
Ligand Pharmaceuticals Incorporated announced today that it has received $2 million in milestone payments from N. V. Organon, a subsidiary of Merck & Co., Inc., stemming from its research collaboration that is due to expire at the end of December. [More]

Posted in: Business / Finance

Tags: , , , , , , , ,

Canadian Arthritis Network to host 2009 Annual Scientific Conference in Vancouver

19. November 2009 22:37
People with arthritis and leading Canadian and international researchers will share the stage under the theme "Decoding Arthritis - A Joint Effort" when the Canadian Arthritis Network (CAN) hosts its 2009 Annual Scientific Conference beginning tonight, in Vancouver, BC. [More]

Posted in: Medical Condition News

Tags: , , , ,

VisEn Medical launches two new agents for imaging quantification

19. November 2009 09:03
VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new OsteoSense® 800 imaging agent for targeting areas of bone turnover and microcalcification in vivo. The new 800 nm OsteoSense agent complements VisEn's OsteoSense 680 and 750 products, and is expected to further expand the utilization of this agent family in enabling in vivo detection, measurement and monitoring of skeletal changes in a wide range of disease states, including arthritis, osteoporosis, and cancer metastasis. [More]

Study: EP4 agonist may reduce gastric bleeding and inflammation

19. November 2009 03:46
Over 300 million patients use non-steroidal anti-inflammatory drugs (NSAIDs) in the world to treat pain, arthritis, fever and other diseases. Nearly 30% of the users suffer from gastric lesions and bleeding. [More]

FDA issues complete response for Rituxan, a drug for treating chronic lymphocytic leukemia

19. November 2009 03:13
Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) issued a complete response on the companies’ applications for Rituxan® (rituximab) plus fludarabine and cyclophosphamide (FC) for the treatment of people with previously untreated and previously treated chronic lymphocytic leukemia (CLL). [More]

Results from Phase IIa clinical trial evaluating VT-111 reported by Viron Therapeutics

19. November 2009 00:49
Viron Therapeutics Inc., a biotechnology company pioneering the development of immune-modulating protein therapeutics derived from pathogens, today reported results from a Phase IIa clinical trial evaluating VT-111 (Serp-1), an anti-inflammatory protein derived from the myxoma virus. [More]

Enzo Biochem to market GeneNews’ ColonSentry in New York and New Jersey

18. November 2009 07:42
Enzo Biochem, Inc. (NYSE:ENZ) today announced that it has entered into an agreement with GeneNews (TSX: GEN), of Toronto, Canada, for exclusive rights to market GeneNews’ ColonSentry™, a proprietary blood test for colorectal cancer, in the states of New York and New Jersey. [More]

Johns Hopkins University to create a Human Proteome Chip using Arrayit's technology

18. November 2009 07:41
Arrayit Corporation announced today that the new High Throughput Biology Center at Johns Hopkins University School of Medicine in Baltimore Maryland purchased Arrayit's proprietary technology to create a Human Proteome Chip to discover biomarkers for autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, autoimmune hepatitis (first identified by Dr. Zhu), lupus, and others. [More]

New market research report on orthopedic instrumentation products

18. November 2009 05:46
Demand for orthopedic instrumentation products is driven by considerable rise in osteoporosis, arthritis, and joint diseases. An aging population, increasingly active lifestyles, and an expanding obese population are factors favoring demand for orthopedic implants. [More]

Posted in: Device / Technology News

Tags: , , , ,

Previous flu infections can reduce the severity of H1N1

18. November 2009 02:09
Researchers at the La Jolla Institute for Allergy & Immunology have found that previous influenza infections may provide at least some level of immunity to the H1N1 "swine" flu. "The question we asked was, "Is the swine flu more like the seasonal flu or like a totally new strain of influenza where there would be no immunity?," said Alessandro Sette, Ph.D., an internationally recognized vaccine expert and director of the La Jolla Institute's Center for Infectious Disease. [More]

PsoriasisDX to present seminar on Genetic Screening for Psoriatic Arthritis

17. November 2009 04:14
A seminar on Genetic Screening for Psoriatic Arthritis will be presented on Tuesday, December 8 from 12-1 PM Pacific Standard Time, hosted by pharmacogenomics research and development innovators PsoriasisDX, pioneers of the world’s first genetic test for psoriatic arthritis (PsA). The seminar will feature leading experts Dr. John Koo and Dr. Wilson Liao. [More]

Phase II clinical study to evaluate Nanocort commenced

17. November 2009 03:22
Galapagos NV announced today that it has started a Phase II clinical study to evaluate Nanocort's effectiveness in treating flares in multiple sclerosis (MS). Nanocort combines less frequent treatment with lower dosage and potentially more effective delivery than other MS flare treatments. [More]

Cold weather can trigger Raynaud's disease

17. November 2009 01:53
Cold weather triggers a painful and sometimes debilitating disorder for millions of Americans who suffer from Raynaud's disease (also known as Raynaud's syndrome or phenomenon). Raynaud's is an autoimmune disorder in which spasms in the blood vessels can interrupt blood flow to the fingers, toes, nose and ears. Exposure to cold triggers the spasms, typically causing the affected area to turn white, then blue, then bright red. Emotional stress can also cause an attack. [More]

Posted in: Medical Condition News

Tags: , , , , , , ,

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.